The FDA approves boosters for minors without testing boosters on minors
Late last week, on December 9, the FDA approved the Emergency Use Authorization (EUA) for the Pfizer COVID-19 vaccine, “authorizing the use of a single booster dose for administration to individuals 16 and 17 years of age.” The booster is to be given at least 6 months after vaccination.
Before we get to the data the FDA cited in the booster for kids aged 16-17, let’s go through the facts:
COVID-19 is not a threat to teenagers aged 16-17. On October 25, we warned that the FDA was about to approve an experimental COVID-19 vaccine for children. It seemed unnecessary to give the EUA Pfizer vaccine to minors, as CDC data showed that for children aged 5-11 years-old, there have been 1.8 million COVID-19 cases and only 138 deaths. For older kids, from our own calculations, there have been approximately 3 million COVID-19 infections for those aged 12-18 years, leading to approximately 400 COVID-19 deaths in those ages. Children who get COVID-19 (including the age range approved for the latest booster) generally have less severe symptoms. Even the CDC concedes that “children are less likely to develop severe illness or die from COVID-19.”
The Pfizer vaccine is particularly dangerous for young men aged 16-17.
As we observed back in October, teenage boys are especially at risk for heart problems – like myocarditis – after getting the Pfizer vaccine:
NO ADVERTISING ON DAWGS BLOG- PAID FOR BY DONATIONS